Founded in 1999, Genfit S.A. specializes in metabolic and inflammatory liver diseases, leveraging its expertise in modulating gene expression through nuclear receptors. The company's therapeutic pipeline includes drug candidates like elafibranor (marketed as Iqirvo through a licensing partnership with Ipsen) for PBC, as well as treatments for ACLF and cholangiocarcinoma. In addition to therapeutics, Genfit develops proprietary diagnostic tools, such as the NIS2+ blood-based technology designed to identify at-risk patients with metabolic dysfunction-associated steatohepatitis (MASH) without the need for invasive liver biopsies. The company generates revenue primarily through milestone payments, royalties from licensing agreements, and strategic partnerships.
